FDA Extends Review Period For AstraZeneca-Merck Partnered Cancer Drug, Lynparza
The FDA will extend the Prescription Drug User Fee Act (PDUFA) date for AstraZeneca Plc (NASDAQ:AZN) and Merck & Co Inc’s (NYSE:MRK) supplemental marketing…
3 Energy Stocks With High Dividend Yields That This Hedge Fund Is Buying
Yacktman Asset Management founder Donald Yacktman was named Morningstar’s “Portfolio Manager of The Year” in 1991 and was awarded the “Portfolio Manager of the Year” by Mutual Fund Letter in 1994.
In the third quarter of 2022, Yacktman initiated a new stake in these three energy stocks with solid yields.
These 2 High-Yield Healthcare REITs Are Holding Up Better Than The Overall Market In 2022
Real estate investment trusts (REITs) operating in the healthcare sector, tend to have a trailing 10-year return of 11.6%, according to SP Global.
Harrow Health Acquires Rights To Novartis’ Five Approved Ophthalmic Products
Harrow Health Inc (NASDAQ:HROW) entered a binding agreement to acquire the exclusive U.S. commercial rights to five FDA‑approved ophthalmic products from Novartis…
Boeing Continues To Convince Congress For 737 MAX 10 Deadline Extension
Boeing Co's (NYSE: BA) Commercial planes CEO said the company would continue to convince Congress to pass legislation for its 737 MAX 7 and MAX 10 regulatory certification even after the deadline.
Bank Of America Say Don’t Buy These 3 Payment Stocks Ahead Of ‘Mild Recession In 2023’
Bank of America analysts said in a note on Tuesday that the investment arm of the bank is staying away from payment stocks including Affirm Holdings Inc (NASDAQ: AFRM), Discover Financial Services (NYSE: DFS), and
Novartis Shares Detailed Results From Experimental Drug For Rare Blood Disorder
Novartis AG (NYSE:NVS) announced detailed results from the pivotal Phase 3 APPLY-PNH trial. The results showed that most of the paroxysmal…
2 Cell Tower REITs With Above-Average Yields: A Great Buy During Coveted Fed Pivot?
SP Global data shows that, over a three-year period, cell tower real estate investment trusts (REITs) had the highest potential returns out of any other REIT sector of nearly 30%.
Takeda To Add Mid-Stage Autoimmune Disease Candidate For $4B
Takeda Pharmaceutical Co Ltd (NYSE:TAK) will acquire NDI-034858 from Nimbus Therapeutics, an oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor for multiple…
Wave Life Sciences Shares Move Higher On Therapeutic Pact With GSK Targeting Genetic Disorders
Wave Life Sciences Ltd (NASDAQ:WVE) and GSK plc (NYSE:GSK) have announced a strategic collaboration to advance oligonucleotide therapeutics, including Wave’s preclinical RNA editing…